Dry shippers that use liquid nitrogen (LN2) are currently used for the cryogenic transport of cell therapy starting material and finished product. However, it can be difficult to predict the manner and time that cold contents can be kept in these devices.
LN2’s finite nature and associated limitations apply pressure to scheduling logistics and can dictate the timing of a therapy’s administration. The VIA Capsule™ system, developed by Cytiva, is a smart, liquid nitrogen-free cryogenic shipper that offers the conditions and functionality required to maintain cell viability before, during, and after transport.
CSL Behring, a biopharmaceutical company that manufacturers biologic therapeutics, evaluated the potential benefits of the cryogenic transportation and short-term storage of cryopreserved cell products using the VIA Capsule™ system. Data was gathered from two independent shipments: Pasadena, California, to King of Prussia, Pennsylvania, and vice versa, using the VIA Capsule™ shipper. To determine any variation in biological quality, the results were compared to control samples at the original site kept in LN2.